SavedAdd your journal

Journals / Journal of Clinical and Experimental Investigations / 2026 / Cilt: 6 Sayı: 1

Surgical treatment of bisphosphonate-associated osteonecrosis of the mandible: Report of two cases

Mandibulada bifosfonat kullanımı sonucunda oluşan osteonekrozun cerrahi tedavisi: iki vaka raporu

İzzet Acikan
Necat Aslan
Halil Durmuş
Yusuf Atalay
Serhat Atılgan
Ferhan Yaman
Pages
61–64
Publication Date
2015-05-10
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

J Clin Exp Invest 2015; 6 (1): 61-64 Key words: Osteonecrosis, Bisphosphonate, jaw

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Bisphosphonates are used to reduce skeletal-related events in patients with bone-consuming diseases, such as osteoporosis and bone metastases.
📊
Key Findings & Data:We present two cases of BRONJ in a 64-year-old female and a 56-year-old female who were admitted to our department with complaints of purulent discharge and pain of the lower jaw.
💡
Conclusion & Impact:J Clin Exp Invest 2015; 6 (1): 61-64 Key words: Osteonecrosis, Bisphosphonate, jaw
🔬Design:Makale
📍Scope:2015 Verileri
⚙️Variables:Osteonekroz · bifosfonat · çene

Abstract

Bisphosphonates are used to reduce skeletal-related events in patients with bone-consuming diseases, such as osteoporosis and bone metastases. Bisphosphonaterelated osteonecrosis of the jaw (BRONJ) is becoming increasingly common with increasing use of bisphosphonates. We present two cases of BRONJ in a 64-year-old female and a 56-year-old female who were admitted to our department with complaints of purulent discharge and pain of the lower jaw. Both patients had been taking bisphosphonate and were diagnosed with jaw osteonecrosis, which can occur due to long-term use of bisphosphonate. The patients underwent medical treatment, including chlorhexidine rinses and antibiotics. Bone debridement was then performed under local anaesthesia. Both patients recovered well. There are many protocols, guidelines and suggestions on the management of BRONJ. For most patients, a conservative approach with minimal local intervention, if necessary, is appropriate, with extensive debridement of necrotic bone when this fails. In a small number of cases, radical resection of bone and reconstruction may be required. J Clin Exp Invest 2015; 6 (1): 61-64 Key words: Osteonecrosis, Bisphosphonate, jaw

Özet

Bifosfonatlar osteoporoz ve kemik metastazı gibi hastalıklardaki kemik yıkımını azaltmaktadır. Artan bifosfonat kullanımıyla birlikte çenelerde görülen bifosfonatla ilişkili osteonekrozda yaygınlaşmaktadır. Kliniğimize alt çenede püy akıntısı ve ağrı şikayeti ile başvuran 64 ve 56 yaşında iki bayan hastanın bifosfonat kullanımıyla ilişkili osteonekroz vakalarını sunuyoruz. Her iki vakada uzun dönem bifosfonat kullanımına bağlı osteonekroz teşhisi konuldu. Tıbbi ve cerrahi tedavi planlaması yapıldı. Hastalara Klorheksidin irrigasyonu ve antibiyotik reçete edildi. Daha sonra lokal anestezi altında kemik debridmanı yapıldı. Her iki hastada çok iyi iyileşme görüldü. Bifosfonatla ilgili osteonekroz tedavisi için önerilen çok sayıda protokol bulunmaktadır. Çoğu hastada konservatif bir yaklaşım olarak nekrotik kemiğin geniş debridmanı ve küçük lokal girişimler yeterlidir ancak çok az vakada bu girişimler başarısız olursa radikal olarak kemiği rezeke etmek gerekmektedir

🔖

Cite This Article

Acikan, İ., Aslan, N., Durmuş, H., Atalay, Y., Atılgan, S., Yaman, F. (2015). Surgical treatment of bisphosphonate-associated osteonecrosis of the mandible: Report of two cases. Journal of Clinical and Experimental Investigations, Cilt: 6 Sayı: 1, 61–64. https://doi.org/10.5799/ahinjs.01.2015.01.0487

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (63)

  1. Pit JV, Joel JO, Alice KM. Surgical treatment of bisphosphonate-associated
  2. osteonecrosis of the jaw. J Cranio
  3. Maxill Surg 2012;40:719-725.
  4. Rathan MS, Gary MM. Bisphosphonate induced osteonecrosis
  5. of the mandible. Eur J Radiology Extra;66:9–11.
  6. Tomoaki S, Mutsumi M, Ryouji T. Bisphosphonate-related
  7. osteonecrosis of the jaw successfully treated with surgical
  8. resection and its histopathological features: A longterm
  9. follow-up report. J Oral Maxill Surg Pathol Med;275:4-8.
  10. Robert E. M. Pamidronate (Aredia) and zoledronate (Zometa)
  11. induced avascular necrosis of the jaws: a growing
  12. epidemic. J Oral Maxill Surg 2003;6:1115-1118.
  13. Robert EM, Yoh S, Michel F, Vishtasb B. Bisphosphonate-induced
  14. exposed bone (osteonecrosis/osteopetrosis)
  15. of the jaws: risk factors, recognition, prevention,
  16. and treatment: J Oral Maxill Surg 2005;63:1567–1575.
  17. Cesar AM. Bisphosphanates and oral cavity avascular
  18. bone necrosis: J Clin Oncol 2003;21:4253-4254.
  19. American Association of Oral and Maxillofacial Surgeons.
  20. Position paperon bisphosphonate-related osteonecrosis
  21. of the jaws; 2006. Available at: http://www.aaoms.
  22. org/docs/position papers/osteonecrosis.pdf.
  23. Cesar AM, Michael AS, Linda SE. Bisphosphonateassociated
  24. osteonecrosis: a long-term complication of
  25. bisphosphonate treatment: Lancet Oncol 2006;7:508–
  26. Ian RR. Osteonecrosis of the jaw — Who gets it, and
  27. why? Bone 2009;44:4–10.
  28. PF Nocini, G Saia, G Bettini. Vascularized fibula flap reconstruction
  29. of the mandible in bisphosphonate-related
  30. osteonecrosis. The J Cancer Surg 2009;35:373-379.
  31. Lerman MA, Xie W, Treister NS. Conservative management
  32. of bisphosphonate-related osteonecrosis of
  33. the jaws Staging and treatment outcomes. Oral Oncol;49:977–983.
  34. Curi MM, Cossolin GS, Koga DH. Bisphosphonate-related
  35. osteonecrosis of the jaws—An initial case series
  36. report of treatment combining partial bone resection
  37. and autologous platelet-rich plasma. J Oral Maxill Surg;69:2465-2472.
  38. Lee CY, David T, Nishime M. Use of platelet- rich plasma
  39. in the management of oral bisphosphonate-associated
  40. osteonecrosis of the jaw: A report of 2 cases. J Oral Implantol;32:371-382.
  41. Pripatnanont P, Nuntanaranont T, Vongvatcharanon S,
  42. et al. The primacy of platelet-rich fibrin on bone regeneration
  43. of various grafts in rabbit’s calvarial defects. J
  44. Cranio Maxill Surg 2013;41:191-200.
  45. Dhoan DMJ, Choukroun AD, et al. Platelet-rich fibrin
  46. (PRF): A second-generation platelet concentrate. Part
  47. III: Leucocyte activation: A new feature for platelet concentrate?
  48. Oral Surgery Oral Med Oral Pathol Oral Radiol
  49. Endod 2006;101:51-55.
  50. Dhoan DMJ, Ehrenfest GM, de Peppo P, et al. Slow
  51. release of growth factors and thrombospondin-1 in
  52. Choukroun’s platelet-rich fibrin (PRF): A gold standard
  53. to achieve for all surgical platelet concentrates technologies.
  54. Growth Factors 2009;27:63-69.
  55. Lin JH, Russell G, Gertz B. Pharmacokinetics of alendronate:
  56. an overview. Int J Clin Pract Suppl 1999;101:18–
  57. Agrillo A, Lingari C, Filiaci F, et al. Ozone Therapy in the
  58. Treatment of Avascular Bisphosphonate-Related Jaw
  59. Osteonecrosis. J Craniofac Surg 2007;18:1071-1075.
  60. Marx RE. Oral and Intravenous Bisphosphonateslnduced
  61. Osteonecrosis of the Jaws: History, etiology,
  62. prevention and treatment. Hanover Park: Quintessence
  63. Books. 2006.